1. Upregulation of Platelet-Activating Factor Receptor Expression and Lyso-Platelet-Activating Factor Isoforms in Human Nasal Polyp Tissues.
- Author
-
Roca-Ferrer J, Pérez-González M, Alobid I, Tubita V, Fuentes M, Bantulà M, Muñoz-Cano R, Valero A, Izquierdo I, and Mullol J
- Abstract
Background: The Platelet-Activating Factor (PAF)/receptor (PAFR) system is involved in asthma and allergic rhinitis; however, its role in chronic rhinosinusitis (CRS) is still unclear. This study aimed to assess the expression of PAFR and the concentration of Lyso-PAF isoforms in the nasal polyps (NP) of patients suffering from CRS with/without comorbidities such as asthma and NSAID-exacerbated respiratory disease (N-ERD) compared to healthy nasal mucosa (NM) from control subjects., Methods: NM ( n = 8) and NP tissues were obtained from patients undergoing surgery for septal deviation/turbinate hypertrophy or endoscopic sinus surgery, respectively. Three phenotypes were studied: CRSwNP with no asthma ( n = 6), CRSwNP with non-steroidal anti-inflammatory drug (NSAID)-tolerant asthma ( n = 6), and CRSwNP with NSAID-exacerbated respiratory disease ( n = 6). PAFR protein and mRNA were assessed via immunochemistry, immunofluorescence, Western blot, and real-time quantitative PCR. Lyso-PAF isoforms (C16, C18, and C18:1) were quantified via mass spectrometry., Results: PAFR protein was expressed in the NM and NP, concretely in epithelial cells and submucosal glands. Compared to NM, PAFR mRNA expression was higher in all NP phenotypes ( p < 0.05) while all Lyso-PAF isoform concentrations were higher in the NP from asthmatic patients ( p < 0.05). Lyso-PAF C16 and C18 concentrations were higher in the NP from asthmatic patients than in the NP from patients without asthma., Conclusions: The PAF/PAFR system could play a pathophysiological role in CRSwNP pathogenesis.
- Published
- 2023
- Full Text
- View/download PDF